The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline

被引:221
作者
Ryken, Timothy C. [2 ]
McDermott, Michael [3 ]
Robinson, Paula D. [4 ]
Ammirati, Mario [5 ]
Andrews, David W. [6 ]
Asher, Anthony L. [7 ]
Burri, Stuart H. [8 ]
Cobbs, Charles S. [9 ]
Gaspar, Laurie E. [10 ]
Kondziolka, Douglas [11 ]
Linskey, Mark E. [12 ]
Loeffler, Jay S. [13 ]
Mehta, Minesh P. [14 ]
Mikkelsen, Tom [15 ]
Olson, Jeffrey J. [16 ]
Paleologos, Nina A. [17 ]
Patchell, Roy A. [18 ]
Kalkanis, Steven N. [1 ]
机构
[1] Henry Ford Hlth Syst, Dept Neurosurg, Hermelin Brain Tumor Ctr, Detroit, MI 48202 USA
[2] Iowa Spine & Brain Inst, Dept Neurosurg, Iowa City, IA USA
[3] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA
[4] McMaster Univ, Evidence Based Practice Ctr, Hamilton, ON, Canada
[5] Ohio State Univ, Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA
[6] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA
[7] Carolina Neurosurg & Spine Associates, Dept Neurosurg, Charlotte, NC USA
[8] Carolinas Med Ctr, Dept Radiat Oncol, Charlotte, NC 28203 USA
[9] Calif Pacific Med Ctr, Dept Neurosci, San Francisco, CA USA
[10] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA
[11] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA
[12] Univ Calif Irvine, Med Ctr, Dept Neurosurg, Orange, CA USA
[13] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
[14] Univ Wisconsin, Dept Human Oncol, Sch Publ Hlth & Med, Madison, WI USA
[15] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA
[16] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA
[17] Northshore Univ Hlth Syst, Dept Neurol, Evanston, IL USA
[18] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA
关键词
Brain metastases; Steroids; Neurologic symptoms; Steroid dosage; Systematic review; Practice guideline; DEXAMETHASONE TREATMENT; CEREBRAL METASTASES; RADIATION-THERAPY; TUMORS; TRIAL; EDEMA;
D O I
10.1007/s11060-009-0057-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Do steroids improve neurologic symptoms in patients with metastatic brain tumors compared to no treatment? If steroids are given, what dose should be used? Comparisons include: (1) steroid therapy versus none. (2) comparison of different doses of steroid therapy. Target population These recommendations apply to adults diagnosed with brain metastases. Recommendations Steroid therapy versus no steroid therapy Asymptomatic brain metastases patients without mass effect Insufficient evidence exists to make a treatment recommendation for this clinical scenario. Brain metastases patients with mild symptoms related to mass effect Level 3 Corticosteroids are recommended to provide temporary symptomatic relief of symptoms related to increased intracranial pressure and edema secondary to brain metastases. It is recommended for patients who are symptomatic from metastatic disease to the brain that a starting dose of 4-8 mg/day of dexamethasone be considered. Brain metastases patients with moderate to severe symptoms related to mass effect Level 3 Corticosteroids are recommended to provide temporary symptomatic relief of symptoms related to increased intracranial pressure and edema secondary to brain metastases. If patients exhibit severe symptoms consistent with increased intracranial pressure, it is recommended that higher doses such as 16 mg/day or more be considered. Choice of Steroid Level 3 If corticosteroids are given, dexamethasone is the best drug choice given the available evidence. Duration of Corticosteroid Administration Level 3 Corticosteroids, if given, should be tapered slowly over a 2 week time period, or longer in symptomatic patients, based upon an individualized treatment regimen and a full understanding of the long-term sequelae of corticosteroid therapy. Given the very limited number of studies (two) which met the eligibility criteria for the systematic review, these are the only recommendations that can be offered based on this methodology. Please see "Discussion" and "Summary" section for additional details.
引用
收藏
页码:103 / 114
页数:12
相关论文
共 17 条
[1]  
ANDERSEN C, 1994, ACT NEUR S, V60, P413
[2]   PALLIATION OF BRAIN METASTASES - FINAL RESULTS OF THE 1ST 2 STUDIES BY THE RADIATION-THERAPY-ONCOLOGY-GROUP [J].
BORGELT, B ;
GELBER, R ;
KRAMER, S ;
BRADY, LW ;
CHANG, CH ;
DAVIS, LW ;
PEREZ, CA ;
HENDRICKSON, FR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1980, 6 (01) :1-9
[3]   Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004 [J].
Brainin, M ;
Barnes, M ;
Baron, JC ;
Gilhus, NE ;
Hughes, R ;
Selmaj, K ;
Waldemar, G .
EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (09) :577-581
[4]  
Gaspar L E, 2000, Radiology, V215 Suppl, P1105
[5]   RADIATION-THERAPY OF CEREBRAL METASTASES - RANDOMIZED PROSPECTIVE CLINICAL-TRIAL [J].
HARWOOD, AR ;
SIMPSON, WJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1977, 2 (11-1) :1091-1094
[6]   EFFECT OF DEXAMETHASONE TREATMENT ON PERITUMORAL BRAIN EDEMA - EVALUATION BY COMPUTED-TOMOGRAPHY [J].
HATAM, A ;
YU, ZY ;
BERGSTROM, M ;
BERGGREN, BM ;
GREITZ, T .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1982, 6 (03) :586-592
[7]   Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? [J].
Hempen, C ;
Weiss, E ;
Hess, CF .
SUPPORTIVE CARE IN CANCER, 2002, 10 (04) :322-328
[8]   Identification of prognostic factors in patients with brain metastases: A review of 1292 patients [J].
Lagerwaard, FJ ;
Levendag, PC ;
Nowak, PJCM ;
Eijkenboom, WMH ;
Hanssens, PEJ ;
Schmitz, PIM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (04) :795-803
[9]   Reliability of the PEDro scale for rating quality of randomized controlled trials [J].
Maher, CG ;
Sherrington, C ;
Herbert, RD ;
Moseley, AM ;
Elkins, M .
PHYSICAL THERAPY, 2003, 83 (08) :713-721
[10]   Defining the impact and contribution of steroids in patients receiving whole-brain irradiation for cerebral metastases [J].
Millar, BM ;
Bezjak, A ;
Tsao, M ;
Sturdza, A ;
Laperriere, N .
CLINICAL ONCOLOGY, 2004, 16 (05) :339-344